NKTR-181, a new molecular entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential. Full story.
© American Academy of Pain Medicine. All Rights Reserved | Privacy Policy | Media Resources | Powered by Insight Marketing Group
American Academy of Pain (AAMP) is a nonprofit, 501(c)(6) tax-exempt organization.